IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
This blend pairs a GHRH analog with a growth hormone secretagogue in a single 5 mg + 5 mg vial. CJC-1295 No DAC (Mod GRF 1-29) stimulates the anterior pituitary to release growth hormone in short pulses that mimic the body’s natural secretion pattern, thanks to its brief half-life. Ipamorelin is a highly selective ghrelin receptor agonist (GHRP class) that triggers GH release without meaningfully raising cortisol or prolactin. Used together, the two act on complementary pathways, amplifying each GH pulse — the synergy behind this blend’s “Hulk” nickname.
— 5 mg + 5 mg Blend Vial —
Reconstitute: Add 2.5 mL (250 units) bacteriostatic water.
Administration: Subcutaneous injection; inject slowly to minimize flushing or a pins-and-needles sensation.
Timing: Best dosed immediately before bedtime, fasted 2–3 hours after your last meal (do not eat afterward). Morning dosing on an empty stomach before breakfast is an acceptable alternative.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.
Schedule: Once-daily injections, 5–7 days per week.
Cycle Length: 12–16 weeks, followed by an 8–16 week washout period.
Goal: Support pulsatile GH release for recovery, body composition, and sleep quality based on preclinical and clinical literature.
Frequency: Inject once daily subcutaneously.
Standard Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Start of cycle | 6 units (0.06 mL), 1x/day | 6 units |
| Titrate up over cycle | Up to 15 units (0.15 mL), 1x/day | up to 15 units |
Begin at 6 units once daily and gradually titrate upward to a maximum of 15 units daily over the course of the cycle, dosing 5–7 days/week.
Maximum Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Start of cycle | 12 units (0.12 mL), 1x/day | 12 units |
| Titrate up over cycle | Up to 30 units (0.30 mL), 1x/day | up to 30 units |
Begin at 12 units once daily and gradually titrate upward to a maximum of 30 units daily over the course of the cycle, dosing 5–7 days/week.
- Promotes fat metabolism (lipolysis).
- Supports lean muscle preservation and growth.
- Accelerates tissue healing in muscle, tendon, and ligament.
- Enhances exercise recovery and repair of training microtrauma.
- Improves collagen synthesis, supporting skin elasticity.
- Potential cosmetic / anti-aging applications studied in peptide research.
- GH release is linked to improved sleep quality.
- Possible improvements in energy, mood, and recovery from fatigue.
- Pulsatile release pattern is less likely to cause receptor desensitization than long-acting GHRH analogs.
With DAC
The Drug Affinity Complex binds the peptide to albumin in the blood, extending its half-life to roughly 6–8 days. One injection can elevate GH and IGF-1 for up to a week — but the constant, sustained GH elevation carries a risk of receptor desensitization.
No DAC (this blend)
A shortened version with a half-life of only ~30 minutes, producing a GH pulse lasting 2–3 hours. This mimics the body’s natural pulsatile secretion pattern and is less likely to cause desensitization.
While side effects are not common, you may experience:
- Injection site reactions (redness, swelling, itching)
- Water retention (magnesium supplementation may help) and bloating
- Mild fatigue or lethargy, usually right after dosing
- Headaches
- Flushing/heat or a pins-and-needles sensation after dosing (inject slowly to mitigate)
- Increased hunger (ghrelin receptor stimulation)
- Nausea, hives, dry mouth, or hyperactivity
- Uncommon: tingling/numbness in extremities, joint pain or stiffness, lightheadedness
- Rare: hypersensitivity/allergic reactions; acromegaly-like symptoms only with very high or prolonged misuse
- Blood sugar / insulin: may temporarily reduce insulin sensitivity; monitor carefully if using insulin or oral hypoglycemics (e.g. metformin, sulfonylureas). May worsen insulin resistance.
- Thyroid medications: GH influences T4→T3 conversion; dose adjustments may be needed.
- Corticosteroids: high-dose or chronic use (e.g. prednisone, dexamethasone) can blunt GH release and reduce efficacy.
- Blood pressure medications: GH-induced fluid retention may reduce diuretic effectiveness or worsen BP control; monitor with beta-blockers, ACE inhibitors, ARBs, or calcium channel blockers.
- Estrogen: can reduce IGF-1 levels, potentially dampening benefits.
- Anabolic/hormone therapies: concurrent use with testosterone, SARMs, or similar may cause synergistic effects on muscle growth, water retention, or joint stress.
- Sedatives/alcohol/sleep medications: may compound dizziness or fatigue.
- Do not use if pregnant or breastfeeding.
- Do not use with active cancer (including pituitary adenomas).
- Do not use with untreated hypothyroidism or an unstable thyroid disorder.
- Do not use with uncontrolled diabetes mellitus; use caution with any blood-sugar regulation issues and monitor closely.
- Do not use with already-elevated GH/IGF-1 levels or acromegaly.
- Do not use with advanced chronic kidney disease.
- Risk of fluid overload, hypertension, or edema in severe cardiovascular disease.
- Not for use in critically ill patients.
- Do not use with an allergy to mannitol or other peptide components; discontinue if hypersensitivity develops.
This blend is itself a synergistic stack of CJC No DAC and Ipamorelin. Common research pairings to extend it include:
- L-Carnitine – Supports fatty-acid transport and oxidation during recomposition
- AOD-9604 – Lipolysis support without glycemic impact
- BPC-157 and/or TB-500 – Connective-tissue, tendon, and joint recovery alongside GH-mediated repair
PubMed-linked citations for verification. Many studies are animal/in-vitro.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 16968799
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822
- The pharmacokinetics, safety and endocrine effects of the ipamorelin, a novel GH-releasing peptide, in human volunteers. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343
- GH-releasing activity of ipamorelin, a new synthetic hexapeptide, after intravenous and subcutaneous administration in adult rats. Growth Horm IGF Res. 1999;9(1):25-30. PMID: 10207505
- Growth hormone-releasing hormone: clinical studies and therapeutic aspects. Neuroendocrinology. 2008;86(3):163-7. PMID: 17684384
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
